乙型肝炎疫苗——从预防到治疗  

Hepatitis B vaccine:From prevention to treatment

作　　者：刘义思 任姗[1] 郑素军[1] 陈新月[1] LIU Yisi;REN Shan;ZHENG Sujun;CHEN Xinyue(First Department of Liver Disease Center,Beijing YouAn Hospital,Capital Medical University,Beijing 100069,China)

机构地区：[1]首都医科大学附属北京佑安医院肝病中心一科,北京100069

出　　处：《临床肝胆病杂志》2024年第5期1021-1025,共5页Journal of Clinical Hepatology

基　　金：国家重点研发计划(2023YFC2308100);首都临床诊疗技术研究及转化应用(Z211100002921059);北京市医院管理中心“青苗”人才计划(QML20211702);北京市卫生健康委员会高层次公共卫生技术人才建设项目(学科带头人-02-14)。

摘　　要：乙型肝炎疫苗的接种是预防HBV感染最经济、有效的方法。分子生物学和基因工程的进步使得疫苗的制造工艺不断完善,乙型肝炎疫苗也从最开始的血源性疫苗逐渐发展至当下所应用的重组疫苗。预防性乙型肝炎疫苗在临床中已试用于HBsAg清除人群以提高抗-HBs水平,且具有安全性及有效性。并且作为治疗CHB新药的多种靶点之一,基于HBsAg的治疗性乙型肝炎疫苗已经在研发和临床试验中。Hepatitis B vaccination is the most economical and effective way to prevent HBV infection.The advances in molecular biology and genetic engineering have continuously improved the manufacturing process of vaccines,and hepatitis B vaccine has gradually developed from the initial plasma-derived vaccine to the currently used recombinant vaccine.Preventive hepatitis B vaccine has been clinically tested in patients with HBsAg seroclearance to increase the level of anti-HBs,with certain safety and efficacy.As one of the multiple targets for new drugs in the treatment of chronic hepatitis B,a therapeutic hepatitis B vaccine based on HBsAg is already in the stages of research and development and clinical trial.

关 键 词：乙型肝炎 慢性 乙型肝炎疫苗 临床试验 

分 类 号：R186[医药卫生—流行病学]